3月4日，据CDE官网消息，江苏恩华药业股份有限公司联合申请药品“盐酸他喷他多口服溶液”，获得临床试验默示许可，受理号CYHL2400265。
公示信息显示，药品“盐酸他喷他多口服溶液”适应症：本品适用于缓解体重超过16 kg的2岁以上儿童和成人的中度至重度急性疼痛，这些疼痛仅可使用阿片类镇痛药才能充分控制。
江苏恩华药业股份有限公司，成立于1999年，位于徐州市，是一家以从事医药制造业为主的企业。企业注册资本101617.6792万人民币，实缴资本49942.9279万人民币。
通过天眼查大数据分析，江苏恩华药业股份有限公司共对外投资了21家企业，参与招投标项目4477次，知识产权方面有商标信息398条，专利信息257条，此外企业还拥有行政许可655个。
主要股东信息显示，江苏恩华药业股份有限公司由徐州恩华投资有限公司持股34.8489%、孙彭生持股4.7339%、陈增良持股3.9293%、付卿持股3.9293%、祁超持股3.7156%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.